Related Experiment Video
Updated: May 17, 2026
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
I V Fedorenko1, G T Gibney, K S M Smalley
1Department of Molecular Oncology, Tampa, FL, USA.
Abstract:
The recent years have seen a significant shift in the expectations for the therapeutic management of disseminated melanoma. The clinical success of BRAF targeted therapy suggests that long-term disease control may one day be a reality for genetically defined subgroups of melanoma patients. Despite this progress, few advances have been made in developing targeted therapeutic strategies for the 50% of patients whose melanomas are BRAF wild-type. The most well-characterized subgroup of BRAF wild-type tumors is the 15-20% of all melanomas that harbor activating NRAS (Neuroblastoma Rat Sarcoma Virus) mutations. Emerging preclinical and clinical evidence suggests that NRAS mutant melanomas have patterns of signal transduction and biological behavior that is distinct from BRAF mutant melanomas. This overview will discuss the unique clinical and prognostic behavior of NRAS mutant melanoma and will summarize the emerging data on how NRAS-driven signaling networks can be translated into novel therapeutic strategies.
Insights
Targeted therapies are improving melanoma treatment for BRAF-mutated tumors. This overview focuses on NRAS-mutant melanoma, exploring its distinct biology and potential new therapeutic strategies for BRAF wild-type patients.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Melanoma treatment has advanced with BRAF inhibitors, offering long-term control for specific patient groups.
- However, targeted therapies for BRAF wild-type melanoma, representing 50% of cases, remain limited.
- NRAS mutations are found in 15-20% of melanomas and define a distinct molecular subtype.
Purpose of the Study:
- To review the unique clinical and prognostic features of NRAS-mutant melanoma.
- To summarize emerging therapeutic strategies targeting NRAS-driven signaling pathways.
Main Methods:
- Review of preclinical and clinical evidence on NRAS-mutant melanoma.
- Analysis of signal transduction patterns and biological behavior distinct from BRAF-mutant melanoma.
Main Results:
- NRAS-mutant melanomas exhibit unique signaling and biological characteristics.
- These distinct patterns offer potential targets for novel therapeutic interventions.
Conclusions:
- NRAS mutations represent a key targetable subgroup within BRAF wild-type melanoma.
- Understanding NRAS-driven networks is crucial for developing effective treatments for this patient population.
